Related Experiment Video

Updated: Feb 10, 2026

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis
05:06

A "Patient-Like" Orthotopic Syngeneic Mouse Model of Hepatocellular Carcinoma Metastasis

Published on: October 24, 2015

12.9K

17-beta-hydroxysteroid dehydrogenase 13 inhibits the progression and recurrence of hepatocellular carcinoma

Jun Chen1, Jian-Yong Zhuo1, Fan Yang1

  • 1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China; Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, China; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China.

Hepatobiliary & Pancreatic Diseases International : HBPD INT
|May 12, 2018
PubMed
Abstract

Insights

Lower expression of 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) in hepatocellular carcinoma (HCC) correlates with poorer patient survival. HSD17B13 inhibits HCC cell growth and may serve as a therapeutic target.

Area of Science:

  • Hepatology
  • Oncology
  • Molecular Biology

Background:

  • 17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13) is downregulated in hepatocellular carcinoma (HCC).
  • The precise function and clinical significance of HSD17B13 in HCC progression were previously unknown.

Purpose of the Study:

  • To elucidate the functional role of HSD17B13 in HCC.
  • To investigate the clinical significance of HSD17B13 expression in HCC patients.

Main Methods:

  • Real-time PCR and immunohistochemistry were used to analyze HSD17B13 mRNA and protein levels in HCC tissues and adjacent non-tumor samples.
  • Statistical analysis, including survival analysis, was performed on patient cohorts.
  • In vitro studies explored the mechanism of HSD17B13's effect on HCC cell cycle progression.

Main Results:

  • HSD17B13 mRNA and protein expression were significantly decreased in HCC tissues compared to non-tumor tissues.
  • Lower HSD17B13 expression in peritumoral tissue was an independent predictor of worse recurrence-free survival in HCC patients.
  • HSD17B13 induced G1 cell cycle arrest and suppressed HCC cell proliferation by upregulating P21, P27, and MMP2.

Conclusions:

  • Reduced HSD17B13 expression is linked to unfavorable survival outcomes in HCC patients.
  • HSD17B13 demonstrates tumor-suppressive properties by inhibiting HCC cell cycle progression.
  • HSD17B13 represents a potential therapeutic target for HCC treatment.
Keywords:
HSD17B13Hepatocellular carcinomaProgressionRecurrenceTumor suppressor

More Related Videos

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

842
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.2K

Related Concept Videos

Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
57.3K
Carbon-13 (¹³C) NMR: Overview01:10

Carbon-13 (¹³C) NMR: Overview

Carbon-13 is a naturally occurring NMR-active isotope of carbon with a low natural abundance of 1.1%. In contrast, carbon-12 is the most abundant isotope of carbon with zero nuclear spin. Therefore, it is NMR inactive. The gyromagnetic ratio of carbon-13 is smaller than that of protons. As a result, carbon-13 resonance is about 6000 times weaker than proton resonance. For a given magnetic field strength, the resonance frequency of carbon-13 is about one-fourth of the resonance frequency for...
7.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
92.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K